---
schema_version: "secwatch.filing_event.v1"
accession: "0001439222-25-000034"
form_type: "8-K"
ticker: "AGIO"
cik: "0001439222"
company_name: "AGIOS PHARMACEUTICALS, INC."
filed_at: "2025-05-01T23:59:59+00:00"
generated_at: "2026-05-23T00:11:56.931266+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Agios Q1 PYRUKYND revenue $8.7M; PDUFA Sept 7 for thalassemia; net loss $89.3M

## Summary
- PYRUKYND net revenue $8.7M in Q1 2025 vs $8.2M in Q1 2024; 136 patients on therapy.
- FDA accepted sNDA for thalassemia with PDUFA goal date September 7, 2025; no advisory committee planned.
- Phase 3 RISE UP in sickle cell disease topline results expected late 2025; potential US launch in 2026.
- Net loss $89.3M in Q1 2025 vs $81.5M in Q1 2024; cash and securities $1.4B as of March 31, 2025.
- Krishnan Viswanadhan appointed Chief Corporate Development and Strategy Officer.

## SEC filing metadata
- accession: 0001439222-25-000034
- form_type: 8-K
- ticker: AGIO
- cik: 0001439222
- company_name: AGIOS PHARMACEUTICALS, INC.
- filed_at: 2025-05-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1439222/000143922225000034/0001439222-25-000034-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1439222/000143922225000034/agio-20250501.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001439222-25-000034
- JSON: https://secwatch.observer/filing/0001439222-25-000034.json
- Plain text: https://secwatch.observer/filing/0001439222-25-000034.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.